ctDNA Predicts Outcomes in Lung Cancer Patients Receiving Radiation Therapy

November 14, 2017

This peer-to-peer exchange highlights results of a study that tested whether analyzing circulating tumor DNA (ctDNA) during treatment with chemoradiotherapy could predict outcomes in patients with localized lung cancer.

In this peer-to-peer exchange, Aadel Chaudhuri, MD, PhD, and Maximilian Diehn, MD, PhD, both of the Stanford School of Medicine in California, discuss results of a study that tested whether analyzing circulating tumor DNA (ctDNA) during treatment with chemoradiotherapy could predict outcomes in patients with localized lung cancer.

Chaudhuri presented results of the study at the 2017 American Society for Radiation Oncology Annual Meeting, held earlier this year in San Diego.